One hypothesis as to why disease recurs in the presence of tamoxifen therapy is that the bulk of the estrogen receptor positive tumor cells are destroyed by treatment, but tumor initiating cells that are negative for estrogen receptor expression persist. Here, ESR1 is linked to neoplasm.